Ranked by reported Q1 2026 13F market value
Share of total reported institutional value in AVDL held by the largest 10 / 25 filers.
| # | Institution | Shares Held | Market Value | QoQ Change | Ownership % | % of Fund |
|---|---|---|---|---|---|---|
| 1 | National Philanthropic Trust | 219K | $3.1M | β | 0.226% | 0.00% |
| 2 | IFP Advisors, Inc | 20 | $426 | 0.0% | 0.000% | 0.00% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). β% of Fundβ shows how much of that investorβs total 13F portfolio is invested in AVDL β a direct measure of their conviction.
Filings activity in AVDL during Q1 2026, grouped by how each filer changed its position.
Institutions that fully closed their AVDL position in Q1 2026
8 quarters of 13F filings Β· Ξ columns show change vs prior quarter
| Quarter | Inst. Holders | Ξ Holders | Ownership % | Ξ Ownership | Total 13F Value | Ξ Value |
|---|---|---|---|---|---|---|
| Q1 2026 | 2 | 99% | 0.15% | 77.91 pp | $3M | 100% |
| Q4 2025 | 198 | +11% | 78.06% | +20.16 pp | $1.64B | +35% |
| Q3 2025 | 179 | +8.5% | 57.90% | +24.58 pp | $1.22B | +74% |
| Q2 2025 | 165 | 1.2% | 33.32% | +5.96 pp | $701M | +22% |
| Q1 2025 | 167 | +9.9% | 27.36% | 11.14 pp | $576M | 29% |
| Q4 2024 | 152 | 8.4% | 38.50% | 5.39 pp | $810M | 12% |
| Q3 2024 | 166 | +20% | 43.89% | 14.43 pp | $923M | 25% |
| Q2 2024 | 138 | β | 58.32% | β | $1.23B | β |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Ξ columns compare to the immediately prior filed quarter.
Quick answers to the most common questions about buying AVDL stock.
Based on Q1 2026 13F filings, institutional ownership of Avadel Pharmaceuticals plc stands at 0.1%, held across 2 reporting institutions.
National Philanthropic Trust is the largest reported institutional holder of AVDL, with approximately 219,296 shares worth $0.00B as of Q1 2026.
No marquee "smart money" managers (Berkshire, Burry, ARK, Tiger Global, Pershing Square, Baupost, etc.) currently appear among the top 25 institutional holders of AVDL.
Our composite Smart Money Score for AVDL is 0 out of 100 (Heavy Distribution). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.
1 institutions opened new positions in AVDL during Q1 2026, while 197 fully exited. 0 added to existing positions and 1 trimmed.
AVDL institutional ownership fell by 77.91 percentage points quarter-over-quarter, with a net change of -196 holders.
The top 10 institutions account for 100.0% of all reported 13F value in AVDL, and the top 25 account for 100.0%.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.
Avadel Pharmaceuticals plc (AVDL) Institutional Ownership